5.30799

AGE Inhibitor, LR-90

• Synonyme(s) : AGE Inhibitor, LR-90, Advanced Glycation Endproducts Inhibitor
• Formule empirique (notation de Hill): C₃₅H₃₄Cl₂N₄O₈
• Numéro CAS: 245075-84-7
• Poids moléculaire : 709.57
• Code UNSPSC : 12352200
• Nomenclature NACRES : NA.77

Propriétés

• Pureté: ≥97% (HPLC)
• Niveau de qualité: 100
• Forme: powder
• Fabricant/nom de marque: Calbiochem^®
• Conditions de stockage: OK to freeze; protect from light
• Couleur: off-white
• Solubilité: DMSO: 100 mg/mL
• Température de stockage: 2-8°C

Description

Description générale

A cell-permeable methylene bisphenylureido derived compound that blocks the formation of advanced glycation endproduct (AGE) by scavenging dicarbonyl intermediates and by chelating transition metals that catalyze the production of AGE. Inhibits metal ion-catalyzed oxidation of ascorbate (IC₅₀ = 275 µM). Exhibits protective effects against diabetic nephropathy, retinopathy, and atherosclerosis and reduces arterial stiffness in diabetic animals (~50 mg/L drinking water) by reducing collagen accumulation and cross-linking. Although it does not affect glycemic condition and body weight in normal and diabetic animals, it reduces plasma triglycerides and glycated hemoglobin levels in diabetic rats and improves their cardiac output and stroke volume. Also shown to suppress S100b and TNFa-induced activation of NF-κB.

Please note that the molecular weight for this compound is batch-specific due to variable water content.

A cell-permeable methylene bisphenylureido derived compound that blocks the formation of advanced glycation endproduct (AGE) by scavenging dicarbonyl intermediates and by chelating transition metals that catalyze the production of AGE. Inhibits metal ion-catalyzed oxidation of ascorbate (IC₅₀ = 275 µM). Exhibits protective effects against diabetic nephropathy, retinopathy, and atherosclerosis and reduces arterial stiffness in diabetic animals (~50 mg/L drinking water) by reducing collagen accumulation and cross-linking. Although it does not affect glycemic condition and body weight in normal and diabetic animals, it reduces plasma triglycerides and glycated hemoglobin levels in diabetic rats and improves their cardiac output and stroke volume. Also shown to suppress S100b and TNFa-induced activation of NF-kB.

Actions biochimiques/physiologiques

Cell permeable: yes

Primary Target
=IF(SGM_MetricTransfer!C11=,,SGM_MetricTransfer!C11)

Conditionnement

Packaged under inert gas

Avertissement

Toxicity: Standard Handling (A)

Reconstitution

Following reconstitution, aliquot and freeze (-20°C). Stock solutions are stable for up to 3 months at -20°C.

Autres remarques

Satheesan, S., et al. 2014. Br. J. Pharmacol.171, 3103.

Nagai, R., et al. 2012. Diabetes.61, 549.
Figarola, J.L., et al. 2008. Diabetologia.51, 882.
Figarola, J.L., et al. 2003. Diabetologia.46, 1140.

Informations légales

CALBIOCHEM is a registered trademark of Merck KGaA, Darmstadt, Germany

Informations sur la sécurité

• Code de la classe de stockage: 11 - Combustible Solids
• Classe de danger pour l'eau (WGK): WGK 3
• Point d'éclair (°F): Not applicable
• Point d'éclair (°C): Not applicable